Quotient Sciences Strengthens Its Top Team with Three New Appointments [Yahoo! Finance]
Evotec SE (EVO)
NASDAQ:AMEX Investor Relations:
eatonvance.com
Company Research
Source: Yahoo! Finance
NOTTINGHAM, England March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector. New appointments include Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer, and Eric Bironneau as Chief Business Officer who will each play a critical role in Quotient Sciences growth and strategic direction. In his new role as Chief Scientific Officer, Dr. Andrew Lewis has responsibility for the company's scientific and technological innovation. Andrew will lead the team of Drug Development Consultants and Scientific Research Fellows to grow Quotient Sciences' global scientific expertise and recognition. During his eight years with Quotient Sciences, Andrew has held various scientific leadership positions, most recently as Senior Vice President, Pharmaceutical Development. Prior to
Show less
Read more
Impact Snapshot
Event Time:
EVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVO alerts
High impacting Evotec SE news events
Weekly update
A roundup of the hottest topics
EVO
News
- Bayer and Evotec Collaborate to Advance Precision Cardiology [Yahoo! Finance]Yahoo! Finance
- Bayer and Evotec Collaborate to Advance Precision CardiologyAccesswire
- Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Evotec SE (NASDAQ: EVO) had its price target lowered by analysts at HC Wainwright from $14.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Evotec: Still A Speculative Buy After A Significant Decline [Seeking Alpha]Seeking Alpha